← board
ABPWW
distress 4/10 · elevated risk$0.01today0% from 52w high
Lead: HER2-positive cancers
Revenue
pre-revenue
Liquidity
$5M
Runway
0.8 yrs
Shares 1y
-93%
Overview
- Market Cap
- $67.81K
- Volume
- 70.00K
- 52 Week Range
- $0.01 – $0.01
- Total Shares
- 5.90M
- Float Shares
- 4.95M
- RVOL
- 1.00x
- Beta
- 0.15
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 3
- first half of 2026trial initiationsecondaryPhase 1ABP-102/CT-P72 · Clinical trials planned to startSEC 8-K
- Sunday, April 27, 2025conferencedata presentationsecondaryABP-102/CT-P72 · Oral presentation of preclinical data at AACR 2025 New Drugs on the Horizon sessionSEC 8-K
- 2024-11-13partnershipAbpro and Atlantic Coastal close business combination; Abpro to trade on Nasdaq under ABP and ABPWWSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — HER2-positive cancers
- ABPOAbpro Holdings, Inc.$1M · D5
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.